Browsing Tag
Johnson & Johnson
119 posts
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as…
July 22, 2024
How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment
Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of…
July 12, 2024
Johnson & Johnson’s TB drug SIRTURO receives full approval from FDA and EC
In a significant development for the treatment of drug-resistant tuberculosis (TB), Johnson & Johnson has announced that SIRTURO…
July 7, 2024
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase…
July 7, 2024
Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial
Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren’s…
June 16, 2024
Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive…
May 30, 2024
Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology…
May 17, 2024
Jury awards $45m in damages in asbestos-related lawsuit against Johnson & Johnson
In a landmark decision, the Circuit Court of Cook County in Chicago has found Johnson & Johnson (NYSE:…
April 21, 2024
Johnson & Johnson announces $13.1bn acquisition of Shockwave Medical to strengthen medtech division
In a monumental move within the medical technology sector, Johnson & Johnson (NYSE: JNJ) has announced its acquisition…
April 8, 2024
Nanobiotix achieves milestone in cancer treatment with NBTXR3, secures $20m from Janssen
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a leader in the field of biotechnology, announced a significant achievement in…
January 30, 2024